Omeros ROE 2012-2026 | OMER
Current and historical return on equity (ROE) values for Omeros (OMER) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Omeros ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2026-06-30 | $0.12B | $-0.11B | -109.01% |
| 2026-03-31 | $0.09B | $-0.16B | -54.34% |
| 2025-12-31 | $0.00B | $-0.20B | 1.53% |
| 2025-09-30 | $-0.12B | $-0.21B | 56.74% |
| 2025-06-30 | $-0.12B | $-0.20B | 62.05% |
| 2025-03-31 | $-0.15B | $-0.17B | 89.94% |
| 2024-12-31 | $-0.16B | $-0.13B | 117.07% |
| 2024-09-30 | $-0.13B | $-0.09B | 142.93% |
| 2024-06-30 | $-0.14B | $-0.06B | 238.30% |
| 2024-03-31 | $-0.12B | $-0.02B | 543.82% |
| 2023-12-31 | $-0.12B | $0.01B | -1275.68% |
| 2023-09-30 | $0.02B | $0.04B | 54.05% |
| 2023-06-30 | $0.04B | $0.03B | 141.38% |
| 2023-03-31 | $0.05B | $0.02B | 303.23% |
| 2022-12-31 | $0.05B | $0.00B | 9600.00% |
| 2022-09-30 | $0.20B | $-0.02B | -1333.33% |
| 2022-06-30 | $0.19B | $-0.07B | -280.14% |
| 2022-03-31 | $0.20B | $-0.12B | -160.00% |
| 2021-12-31 | $0.19B | $-0.18B | -109.76% |
| 2021-09-30 | $-0.12B | $-0.21B | 58.22% |
| 2021-06-30 | $-0.14B | $-0.17B | 82.25% |
| 2021-03-31 | $-0.14B | $-0.15B | 96.79% |
| 2020-12-31 | $-0.14B | $-0.13B | 109.38% |
| 2020-09-30 | $-0.13B | $-0.12B | 105.52% |
| 2020-06-30 | $-0.11B | $-0.14B | 78.97% |
| 2020-03-31 | $-0.09B | $-0.13B | 68.88% |
| 2019-12-31 | $-0.08B | $-0.13B | 66.40% |
| 2019-09-30 | $-0.08B | $-0.12B | 63.54% |
| 2019-06-30 | $-0.10B | $-0.11B | 91.82% |
| 2019-03-31 | $-0.12B | $-0.09B | 132.24% |
| 2018-12-31 | $-0.13B | $-0.07B | 185.40% |
| 2018-09-30 | $-0.12B | $-0.04B | 271.19% |
| 2018-06-30 | $-0.09B | $-0.02B | 445.57% |
| 2018-03-31 | $-0.07B | $-0.02B | 348.72% |
| 2017-12-31 | $-0.05B | $-0.02B | 218.56% |
| 2017-09-30 | $-0.06B | $-0.03B | 170.99% |
| 2017-06-30 | $-0.06B | $-0.04B | 154.60% |
| 2017-03-31 | $-0.06B | $-0.04B | 157.96% |
| 2016-12-31 | $-0.07B | $-0.04B | 181.33% |
| 2016-09-30 | $-0.07B | $-0.04B | 195.68% |
| 2016-06-30 | $-0.07B | $-0.03B | 236.80% |
| 2016-03-31 | $-0.08B | $-0.02B | 458.82% |
| 2015-12-31 | $-0.08B | $0.00B | 6080.00% |
| 2015-09-30 | $-0.08B | $-0.01B | 1400.00% |
| 2015-06-30 | $-0.08B | $-0.01B | 750.00% |
| 2015-03-31 | $-0.08B | $-0.02B | 515.25% |
| 2014-12-31 | $-0.07B | $-0.02B | 389.47% |
| 2014-09-30 | $-0.06B | $-0.01B | 431.37% |
| 2014-06-30 | $-0.05B | $-0.01B | 425.00% |
| 2014-03-31 | $-0.05B | $-0.01B | 383.67% |
| 2013-12-31 | $-0.04B | $-0.02B | 228.57% |
| 2013-09-30 | $-0.05B | $-0.02B | 311.86% |
| 2013-06-30 | $-0.05B | $-0.01B | 500.00% |
| 2013-03-31 | $-0.04B | $-0.01B | 355.56% |
| 2012-12-31 | $-0.04B | $-0.01B | 371.43% |
| 2012-09-30 | $-0.04B | $-0.01B | 400.00% |
| 2012-06-30 | $-0.04B | $-0.01B | 388.89% |
| 2012-03-31 | $-0.03B | $0.00B | 2480.00% |
| 2011-12-31 | $-0.03B | $0.01B | -504.35% |
| 2011-09-30 | $-0.03B | $0.01B | -212.24% |
| 2011-06-30 | $-0.03B | $0.02B | -158.82% |
| 2011-03-31 | $-0.03B | $0.02B | -136.36% |
| 2010-12-31 | $-0.03B | $0.03B | -109.09% |
| 2010-09-30 | $-0.03B | $0.03B | -87.22% |
| 2010-06-30 | $-0.03B | $0.02B | -104.17% |
| 2010-03-31 | $-0.02B | $0.02B | -139.39% |
| 2009-12-31 | $-0.02B | $0.01B | -289.66% |
| 2009-06-30 | $-0.02B | 0 | 0.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $1.264B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $178.385B | 19.60 |
| Medtronic (MDT) | Ireland | $119.983B | 16.40 |
| Stryker (SYK) | United States | $108.118B | 20.21 |
| EssilorLuxottica (ESLOY) | France | $79.433B | 0.00 |
| Boston Scientific (BSX) | United States | $65.288B | 14.03 |
| Lonza Group Ag (LZAGY) | Switzerland | $45.930B | 0.00 |
| Medline (MDLN) | United States | $42.846B | 0.00 |
| Agilent Technologies (A) | United States | $41.387B | 24.22 |
| ResMed (RMD) | United States | $32.167B | 19.96 |
| GE HealthCare Technologies (GEHC) | United States | $29.021B | 13.88 |
| Koninklijke Philips (PHG) | Netherlands | $24.651B | 13.13 |
| Terumo (TRUMY) | Japan | $21.625B | 20.65 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.414B | 11.38 |
| Baxter (BAX) | United States | $12.336B | 11.64 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.926B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.854B | 39.71 |
| Demant (WILYY) | Denmark | $9.592B | 0.00 |
| Insulet (PODD) | United States | $9.557B | 23.48 |
| Sunny Optical Technology (SNPTF) | China | $9.142B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.548B | 20.15 |
| Raia Drogasil SA - (RADLY) | $4.931B | 0.00 | |
| Haemonetics (HAE) | United States | $4.837B | 21.22 |
| BillionToOne (BLLN) | United States | $4.757B | 144.03 |
| DiaSorin S.p.A (DSRLF) | Italy | $4.705B | 0.00 |
| Envista Holdings (NVST) | United States | $4.142B | 17.54 |
| ICU Medical (ICUI) | United States | $3.939B | 23.52 |
| AtriCure (ATRC) | United States | $2.838B | 242.57 |
| Neogen (NEOG) | United States | $2.606B | 45.96 |
| Curaleaf Holdings (CURLD) | Canada | $2.388B | 0.00 |
| Curaleaf Holdings (CURLF) | United States | $2.356B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $2.256B | 10.77 |
| Trulieve Cannabis (TRLV) | United States | $2.238B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.207B | 0.00 |
| Perrigo (PRGO) | Ireland | $1.894B | 5.46 |
| LeMaitre Vascular (LMAT) | United States | $1.847B | 29.69 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $1.798B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.736B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.733B | 221.44 |
| Phibro Animal Health (PAHC) | United States | $1.459B | 11.20 |
| Green Thumb Industries (GTBIF) | United States | $1.428B | 15.23 |
| Kestra Medical Technologies (KMTS) | United States | $1.410B | 0.00 |
| Lumexa Imaging Holdings (LMRI) | United States | $1.094B | 0.00 |
| CeriBell (CBLL) | United States | $0.934B | 0.00 |
| InMode (INMD) | Israel | $0.856B | 11.91 |
| AdaptHealth (AHCO) | United States | $0.802B | 16.80 |
| VAREX IMAGING (VREX) | United States | $0.777B | 17.09 |
| QuidelOrtho (QDEL) | United States | $0.763B | 8.24 |
| Glass House Brands (GLAS) | United States | $0.760B | 0.00 |
| Valneva SE (VALN) | France | $0.633B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.582B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.564B | 0.00 |
| Brainsway (BWAY) | Israel | $0.548B | 30.98 |
| Evolus (EOLS) | United States | $0.524B | 0.00 |
| Cerus (CERS) | United States | $0.514B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.512B | 0.00 |
| Vireo Growth (VREOD) | United States | $0.451B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.438B | 0.00 |
| Verano Holdings (VRNOD) | United States | $0.425B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.422B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.395B | 8.28 |
| Cresco Labs (CRLBF) | United States | $0.373B | 0.00 |
| SNDL (SNDL) | Canada | $0.353B | 0.00 |
| Village Farms (VFF) | Canada | $0.347B | 15.78 |
| Viemed Healthcare (VMD) | United States | $0.337B | 24.56 |
| Sanara MedTech (SMTI) | United States | $0.321B | 159.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.294B | 0.00 |
| MacroGenics (MGNX) | United States | $0.268B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.247B | 13.14 |
| High Tide (HITI) | Canada | $0.234B | 52.60 |
| OraSure Technologies (OSUR) | United States | $0.232B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.225B | 21.55 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| TerrAscend (TSNDF) | Canada | $0.205B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.194B | 0.00 |
| Exagen (XGN) | United States | $0.178B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| Jin Medical (ZJYL) | China | $0.155B | 0.00 |
| Organigram Global (OGI) | Canada | $0.152B | 0.00 |
| Apyx Medical (APYX) | United States | $0.127B | 0.00 |
| Quanterix (QTRX) | United States | $0.118B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.53 |
| ImmuCell (ICCC) | United States | $0.088B | 121.38 |
| Accendra Health (ACH) | United States | $0.086B | 4.87 |
| FitLife Brands (FTLF) | United States | $0.086B | 11.30 |
| Jushi Holdings (JUSHF) | United States | $0.083B | 0.00 |
| Sharps Technology (STSS) | United States | $0.065B | 0.00 |
| InterCure (INCR) | Israel | $0.058B | 0.00 |
| Hongchang (HCIL) | China | $0.052B | 0.00 |
| Biote (BTMD) | United States | $0.050B | 4.12 |
| Nephros (NEPH) | United States | $0.048B | 40.27 |
| Veru (VERU) | United States | $0.040B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.037B | 17.71 |
| United-Guardian (UG) | United States | $0.033B | 13.26 |
| Rockwell Medical (RMTI) | United States | $0.031B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.022B | 0.00 |
| Modular Medical (MODD) | United States | $0.021B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.019B | 0.00 |
| Bonk (BNKK) | United States | $0.011B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.006B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Agape ATP (ATPC) | $0.002B | 0.00 | |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.000B | 0.00 |
| INLIF (INLF) | China | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |